T-Cell Prolymphocytic Leukemia
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-T-PLL |
|---|---|
| Type | Disease |
| Aliases | T-PLLT-cell PLLT-клітинна пролімфоцитарна лейкемія |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9834/3 |
|---|---|
| icd_10 | C91.6 |
| who_classification | Mature T-cell and NK-cell neoplasms — T-cell prolymphocytic leukaemia per WHO 5th ed. |
Notes
STUB. Alemtuzumab IV — disease-defining therapy (anti-CD52 universally expressed). SC route менш ефективна. ATM mutation testing — important для prognosis. Allo-SCT planning одразу після diagnosis для fit pts.
Used By
Algorithms
ALGO-T-PLL-1L- ALGO-T-PLL-1LALGO-T-PLL-2L- ALGO-T-PLL-2L
Indication
IND-T-PLL-1L-ALEMTUZUMAB- IND-T-PLL-1L-ALEMTUZUMABIND-T-PLL-2L-VENETOCLAX-ALEMTUZUMAB- IND-T-PLL-2L-VENETOCLAX-ALEMTUZUMAB
Questionnaires
QUEST-T-PLL-1L-STUB- T-Cell Prolymphocytic Leukemia — first line
Red flag
RF-T-PLL-FRAILTY-AGE- Age >75 OR not alloSCT-eligible (ECOG ≥3, severe organ dysfunction) — alemtuzumab still a...RF-T-PLL-HIGH-RISK-BIOLOGY- Complex karyotype (≥3 abnormalities), TP53 mutation/deletion, or Ki-67 >40% — aggressive...RF-T-PLL-INFECTION-SCREENING- CMV PCR + HBV/HCV/HIV serology + PCP prophylaxis pre-alemtuzumab — alemtuzumab reactivate...RF-T-PLL-ORGAN-DYSFUNCTION- Severe cytopenia (ANC <0.5 OR platelets <50 OR Hgb <8) at diagnosis — disease-driven marr...RF-T-PLL-TRANSFORMATION-PROGRESSION- Failure to achieve CR after 12 weeks alemtuzumab IV OR rapid relapse — alloSCT urgently;...
Sources
SRC-ESMO-PTCL-2024- ESMO Clinical Practice Guideline on Peripheral T-cell Lymphomas